Voyageur Pharmaceuticals Ltd. VYYRF
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 90.71% | 49.03% | 86.50% | 82.92% | 50.14% |
| Depreciation & Amortization | -20.00% | -27.27% | -33.33% | -30.77% | -28.57% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 93.36% | 50.62% | 87.14% | 83.80% | 50.01% |
| Operating Income | -90.63% | -48.98% | -86.38% | -82.99% | -50.01% |
| Income Before Tax | -77.22% | -52.95% | -101.97% | -99.17% | -61.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -77.22% | -52.95% | -101.97% | -99.17% | -61.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.22% | -52.95% | -101.97% | -99.17% | -61.53% |
| EBIT | -90.63% | -48.98% | -86.38% | -82.99% | -50.01% |
| EBITDA | -90.72% | -49.04% | -86.51% | -83.14% | -50.14% |
| EPS Basic | -52.88% | -29.09% | -68.13% | -71.08% | -46.48% |
| Normalized Basic EPS | -52.31% | -28.99% | -65.52% | -74.51% | -47.73% |
| EPS Diluted | -52.88% | -29.09% | -68.13% | -71.08% | -46.48% |
| Normalized Diluted EPS | -52.31% | -28.99% | -65.52% | -74.51% | -47.73% |
| Average Basic Shares Outstanding | 18.12% | 19.60% | 20.36% | 14.67% | 10.90% |
| Average Diluted Shares Outstanding | 18.12% | 19.60% | 20.36% | 14.67% | 10.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |